Saudi Arabia Pharmaceutical CDMO Market to Grow with a CAGR of 5.45% through 2030

Increasing Domestic Demand for Pharmaceuticals and Health System Modernization is expected to drive the Saudi Arabia Pharmaceutical CDMO Market growth in the forecast period, 2026-2030

According to TechSci Research report, “Saudi Arabia Pharmaceutical CDMO Market – By Region, Competition, Forecast & Opportunities, 2030F”, the Saudi Arabia Pharmaceutical CDMO Market stood at USD 1625.85 Million in 2024 and is anticipated to grow with a CAGR of 5.45% in the forecast period, 2026-2030.

The government is significantly investing in the pharmaceutical and healthcare sectors to diversify the economy. This includes initiatives like Lifera, a biopharmaceutical CDMO supported by the Public Investment Fund (PIF), designed to reduce reliance on foreign pharmaceutical imports, create local employment opportunities, and foster the growth of a competitive manufacturing industry. These efforts are complemented by the government's streamlined regulatory processes and incentives that create a conducive environment for local CDMOs to thrive.

Saudi Arabia is increasingly focusing on biologics, vaccines, and monoclonal antibodies as high-growth therapeutic areas. This shift toward biologics is expected to drive demand for advanced CDMO services, particularly in the production of cell and gene therapies, as companies seek local manufacturing partners capable of managing the complex production processes inherent to these therapies. The integration of advanced technologies, such as automation, AI, and digitalization, is enhancing the efficiency, quality, and speed of pharmaceutical production in Saudi Arabia. Local CDMOs are increasingly adopting these cutting-edge technologies, aligning with the growing demand for precision medicine and personalized treatments. As a result, Saudi Arabia is positioning itself as a competitive player in the global pharmaceutical market by improving its manufacturing capabilities.

The evolving regulatory landscape in Saudi Arabia plays a crucial role in fostering the growth of the pharmaceutical CDMO sector. The Saudi Food and Drug Authority (SFDA) has introduced more transparent and efficient approval processes, designed to expedite product market entry. These regulatory reforms make Saudi Arabia an attractive destination for pharmaceutical manufacturing investments, strengthening its position as a regional hub for pharmaceutical production. Saudi Arabia's pharmaceutical CDMO market expands, it faces intense competition from established global players, particularly those in Asia, Europe, and North America. These regions have more mature ecosystems, robust infrastructure, access to advanced technologies, and extensive talent pools. Global CDMOs from these regions benefit from economies of scale, well-established supply chains, and a wider range of services, which enable them to offer lower production costs.

Saudi CDMOs must overcome these competitive pressures by differentiating themselves through specialized services, such as biologics production, and by emphasizing cost-effectiveness and reliability. However, the relatively early stage of Saudi Arabia’s pharmaceutical manufacturing industry, combined with the challenges mentioned earlier, limits its ability to directly compete with these established players. Additionally, local CDMOs face barriers to entering certain markets due to the established reputation and trust enjoyed by their global counterparts, making it difficult for Saudi companies to attract international clients and expand their market share.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Saudi Arabia Pharmaceutical CDMO Market”

The Saudi Arabia Pharmaceutical CDMO Market is segmented into product, application, workflow, regional distribution, and company.

Based on its application, the Oncology segment has emerged as the predominant market leader, Cancer is one of the leading causes of death in Saudi Arabia, with the number of diagnosed cancer cases steadily increasing. According to the Saudi Health Council, the country is experiencing a growing cancer burden, with an annual rise in both the prevalence of cancer and the demand for oncology treatments. This increasing incidence of cancer has driven a surge in the demand for oncology drugs and biologics, which in turn fuels the need for specialized manufacturing capabilities in the pharmaceutical CDMO sector.

As the demand for cancer treatments such as chemotherapy, immunotherapy, and targeted therapies increases, local pharmaceutical manufacturers are increasingly focusing on offering services that cater to these complex therapies. Oncology treatments, particularly those involving biologics and monoclonal antibodies, require specialized manufacturing processes, including cell line development, advanced bioprocessing, and regulatory compliance. This has led to the establishment of more advanced CDMO facilities in Saudi Arabia, designed to meet the specific requirements of the oncology market. The oncology segment is characterized by rapid advances in treatment options, including personalized medicine, immunotherapy, CAR-T (Chimeric Antigen Receptor T-cell) therapies, and monoclonal antibodies. These therapies are highly complex, requiring cutting-edge manufacturing techniques, stringent quality controls, and specialized expertise. Saudi Arabian CDMOs are increasingly focusing on these advanced therapies, which require sophisticated biologic production capabilities, clean room environments, and adherence to international regulatory standards. The shift towards biologics in oncology, including monoclonal antibodies and gene therapies, presents significant opportunities for local CDMOs in Saudi Arabia. CDMOs are adopting advanced manufacturing processes such as cell culture and fermentation technology to produce biologics for oncology treatments. This specialized manufacturing capability is positioning Saudi Arabia as a competitive player in the high-value oncology sector, attracting global pharmaceutical companies looking for local manufacturing partners with expertise in these intricate production processes

Major companies operating in Saudi Arabia Pharmaceutical CDMO Market are:

• Tabuk Manufacturing Company
• Lifera
• Saudi Bio, Kingdom of Saudi Arabia
• Fresenius Kabi MENA
• Hikma Pharmaceuticals PLC
• Pfizer Scientific Technical Limited Company
• Novartis AG

Download Free Sample Report

Customers can also request for 10% free customization on this report

“The Saudi Arabian pharmaceutical CDMO market is poised for significant growth, driven by a combination of strategic government initiatives, increasing domestic demand, and a focus on specialized therapeutic areas such as oncology, biologics, and biosimilars. With the government's Vision 2030 supporting the diversification of the economy and fostering a favorable environment for local manufacturing, Saudi Arabia is positioning itself as a competitive player in the global pharmaceutical supply chain. While challenges such as competition from established global players remain, the Kingdom's investments in advanced manufacturing technologies, regulatory improvements, and infrastructure development create a strong foundation for continued expansion. As local CDMOs enhance their capabilities and expand their service offerings, Saudi Arabia is set to become a key hub for pharmaceutical development and production in the Middle East and beyond.,” said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.

“Saudi Arabia Pharmaceutical CDMO Market, By Product (API, Synthetic, Solid, Liquid, Biotech, Drug Product, Oral Solid Dose, Semi-solid Dose, Liquid Dose, Others), By Work Flow (Clinical, Commercial), By Application (Oncology, Small Molecule, Biologics, Infectious Diseases, Neurological Disorders, Cardiovascular Diseases, Metabolic Disorders, Autoimmune Diseases, Respiratory Diseases, Ophthalmology, Gastrointestinal Disorders, Hormonal Disorders, Hematological Disorders, Others), By Region, Competition, Forecast & Opportunities, 2020-2030F”, has evaluated the future growth potential of Saudi Arabia Pharmaceutical CDMO Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Saudi Arabia Pharmaceutical CDMO Market.

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]